Get the Stockscreener App
3.78
4.55%
-0.18
After Hours:
3.86
0.08
+2.12%
Wave Life Sciences Ltd stock is traded at $3.78, with a volume of 4.06M.
It is down -4.55% in the last 24 hours and down -28.00% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$3.96
Open:
$4
24h Volume:
4.06M
Relative Volume:
1.32
Market Cap:
$744.84M
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-3.5853
EPS:
-1.0543
Net Cash Flow:
$-186.52M
1W Performance:
-13.10%
1M Performance:
-28.00%
6M Performance:
-69.27%
1Y Performance:
-43.24%
1-Day Range:
$3.745
$4.00
1-Week Range:
$3.745
$4.45
52-Week Range:
$3.745
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
3.78 | 744.84M | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-26 | Resumed | Truist | Buy |
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide - marketscreener.com
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Wave Life Sciences starts Phase 2a obesity trial for WVE-007 - Investing.com India
Wave Life Sciences starts Phase 2a obesity trial for WVE-007 By Investing.com - Investing.com South Africa
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - GlobeNewswire
JPMorgan resumes Wave Life Sciences stock rating at Neutral By Investing.com - Investing.com Australia
JPMorgan resumes Wave Life Sciences stock rating at Neutral - Investing.com
Wave Life Sciences stock hits a 52-week low at USD 4.20 - ad-hoc-news.de
Wave Life Sciences Names Monika Vnuk Chief Business Officer - citybiz
Wave Life Sciences appoints Monika Vnuk as chief business officer By Investing.com - Investing.com Australia
Wave Life Sciences appoints Monika Vnuk as chief business officer - Investing.com
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - manilatimes.net
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer - Quiver Quantitative
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Nigeria
Wave Life Sciences at Cantor conference: RNA editing gains traction - investing.com
WAVE Life Sciences (WVE) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Wave Life Sciences stock holds steady ahead of Cantor healthcare conference appearance - ad-hoc-news.de
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - GlobeNewswire
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences stock trades quietly as investors focus on recent clinical progress - ad-hoc-news.de
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold" - MarketBeat
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Wave Life Sciences targets fat loss without sacrificing muscle - Longevity.Technology
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher - Moomoo
Wave Life Sciences (WVE) Pulls Back 5.2% to $5.13 as Support Holds at $4.87Thematic ETF Flow - vinanet.vn
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026) - Stock Titan
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones - Stock Traders Daily
Wave Life Sciences, Inc.: Top Mutual Funds Holders | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Target Price Consensus and Analysts Recommendations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Performance & Quotes, WVE Stock Price on Nasdaq Exchange - marketscreener.com
Wave Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Financial Data Forecasts Estimates and Expectations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc. Stock (WVE)Quote Nasdaq - marketscreener.com
Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
WAVE Life Sciences Ltd at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q2 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences Ltd.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences (WVE) Director Adrian Rawcliffe Sells 12,700 Shares, Reducing Stake to Zero - GuruFocus
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares - MarketBeat
Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan - Stock Titan
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover - Yahoo Finance
Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales - simplywall.st
Wave Life Sciences Ltd. SEC Filing (Aug 12, 2026) - Stock Titan
Wave Life Sciences at canaccord growth conference: obesity and RNA bets - Investing.com Canada
BofA Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $17 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week LowHere's What Happened - MarketBeat
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):